Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells

Cancer Research

Volumn 61, Issue 13, 2001, Pages 5106-5115

  Dai, Y ^a   Yu, C ^a   Singh, V ^a   Tang, L ^a   Wang, Z ^a   McInistry, R ^a   Dent, P ^a   Grant, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BUTADIENES; CASPASES; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HL-60 CELLS; HUMANS; JURKAT CELLS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; STAUROSPORINE; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 0035393498     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily
2. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
3. 2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216
4. 2 checkpoint inhibitor
5. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
6. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
7. Interactions between 2-fluoroadenine 9-β-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells
8. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
9. Potentiation of 1-β-D-arabinofurano-sylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01)
10. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
11. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells
12. 1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent
13. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
14. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans
15. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor UCN-01
16. Modulation of clinical drug resistance in a B-cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm
17. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
18. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis
19. The MAPK signaling cascade
20. Serine/threonine protein kinases and apoptosis
21. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
22. The stress-activated protein kinase pathways
23. A synthetic inhibitor of the mitogen-activated protein kinase cascade
24. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
25. The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo
26. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
27. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling
28. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade
29. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofurano-sylcytosine-mediated mitochondrial dysfunction and apoptosis
30. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays
31. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
32. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 1-3-3 binding
33. Caffeine inhibits the checkpoint kinase ATM
34. Mitochondrial regulation of cell death: Mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death
35. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
36. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
37. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAFI/CIPI/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells
38. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C
39. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
40. Induction of a common pathway of apoptosis by staurosporine
41. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C
42. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: Lack of direct association with inhibition of protein kinase C
43. Specificity and mechanism of action of some commonly used protein kinase inhibitors
44. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras
45. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin
46. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
47. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells
48. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
49. Collapse of the inner mitochondrial transmembrane potential is not required for apoptosis of HL60 cells
50. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
51. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
52. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
53. Inactivation of Bcl-2 by phosphorylation
54. Regulation of cell death protease caspase-9 by phosphorylation
55. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes
56. Structural and biochemical basis of apoptotic activation by Smac/DIABLO
57. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
58. Cell cycle and apoptosis: Common pathways to life and death
59. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity
60. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons
61. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis
62. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase
63. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway
64. Cip1/WAFI/MDA6 expression and mitogen-activated kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells